Clinical trials: Pulmonary Vascular Disorder
Pulmonary Arterial Hypertension
Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants
The purpose of this study was to measure the long-term safety and efficacy profile of LTP001 in participants with pulmonary arterial hypertension (PAH).
- Trial name
- NCT05764265
- Testing
- LTP001
- Where
- 12 sites in United States, Argentina and 5 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
PR3-AAV Resilient Remission or PRRR
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (PR3-AAV).
- Conditions
- Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
- Trial name
- NCT05376319
- Testing
- Obinutuzumab, Rituximab
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Chronic Kidney Disease, Diabetes
Improving Chronic Disease Management With Pieces
ICD-Pieces (Parkland Intelligent e-Coordination and Evaluation System) trial is a National Institutes of Health (NIH) Healthcare Systems(HCS) Collaboratory demonstration project to improve management of patients with a triad of…
- Conditions
- Chronic Kidney Disease, Diabetes, Hypertension, High BP
- Trial name
- ICD-Pieces (NCT02587936)
- Testing
- Collaborative Model of Primary care and Subspecialty care
- Where
- 4 sites in United States
- Volunteers
- 18,268 people
- Sponsor
- University of Texas Southwestern Medical Center
Pulmonary Veno Occlusive Disease
Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis
The objective of this study is to conduct a pilot study using biologic agents Avastin and Gleevec to treat progression of multivessel intraluminal pulmonary vein stenosis in children.
- Trial name
- PVS (NCT00891527)
- Testing
- Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Boston Children's Hospital
Pulmonary Hypertension, Diastolic Left Ventricular Dysfunction
Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction
This is a single center, open-label trial designed to assess the safety and efficacy of ranolazine (Ranexa) in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction.
- Trial name
- NCT02133352
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Boston University
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
This was a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind, placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary hypertension (PH) associated with heart failure…
- Trial name
- NCT03037580
- Testing
- Oral treprostinil
- Where
- 82 sites in United States
- Volunteers
- 84 people
- Sponsor
- United Therapeutics
Heart Failure, Pulmonary Hypertension
Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure
This study is a multi-center, prospective, randomized, double blind, placebo-controlled clinical trial. Subjects in the study will be adults with New York Heart Association (NYHA) Class II-IV heart failure (HF) due to left…
- Trial name
- PITCH-HF (NCT01910389)
- Testing
- Tadalafil
- Where
- 63 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Carelon Research
Aortic Stenosis
Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis
Pulmonary hypertension is common in patients with aortic stenosis and is associated with worse operative and long-term outcomes.
- Trial name
- NCT01060020
- Testing
- Sildenafil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Pulmonary Embolism
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using low dose r-tPA for the treatment of acute submassive pulmonary embolism.
- Trial name
- RESCUE (NCT04248868)
- Testing
- The Bashir™ Endovascular Catheter, r-tPA
- Where
- 19 sites in United States
- Volunteers
- 109 people
- Sponsor
- Thrombolex, Inc.
Chronic Obstructive Pulmonary Disease, Heart Failure
PATient Navigator to rEduce Readmissions
Staying out of the hospital is valued by patients and their caregivers. Their interests converge with those of hospitals now that high 30-day readmission rates for some conditions place hospitals at risk for financial penalties…
- Conditions
- Chronic Obstructive Pulmonary Disease, Heart Failure, Sickle Cell Disease, Myocardial Infarction
- Trial name
- PArTNER (NCT02114515)
- Testing
- Hospital usual care, Navigator intervention, Peer-led telephone support line
- Where
- United States
- Volunteers
- 1,029 people
- Sponsor
- University of Illinois Chicago
Heart Failure
Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement
Research study evaluating the individual and combined effects of inhaled nitric oxide (iNO) and inhaled prostacyclin (iPGI2), on the function of the right heart after surgery for either heart transplant or for left ventricular…
- Trial name
- NCT01717209
- Testing
- Nitric Oxide, Prostacyclin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Stanford University
Churg-Strauss Syndrome, Eosinophilic Asthma
Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
In this project the investigators will look for auto-antibodies to relevant proteins both in native form and importantly in post-translationally modified forms.
- Conditions
- Churg-Strauss Syndrome, Eosinophilic Asthma, Eosinophilic Esophagitis, Eosinophilic Pneumonia
- Trial name
- IDEA (NCT04671446)
- Testing
- Autoantibody ELISA, Granulocyte Immunofluorescence
- Where
- 2 sites in United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Pulmonary Embolism, Deep Vein Thrombosis
Angel® Catheter Early Feasibility Clinical Study
The primary objective of this clinical trial is to obtain initial insights into the safety of the Angel® Catheter in critically ill subjects with high risk of venous thromboembolism (VTE) disease AND who are not receiving…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Trial name
- NCT01847196
- Testing
- Angel® Catheter
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- BiO2 Medical
Pulmonary Hypertension
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study was an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who were currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- NCT00325442
- Testing
- Oral treprostinil (UT-15C) sustained release tablets
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 354 people
- Sponsor
- United Therapeutics
Hypertension, Pulmonary
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
This is a single center, open-label, randomized, single-dose, three-period cross-over study in healthy participants. The aim of this study is to provide clinically relevant information on the pharmacokinetic (PK) and safety…
- Trial name
- NCT04095286
- Testing
- AMB new formulation (1 mg), Reference AMB (5 mg)
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Primary Graft Dysfunction
Sodium Nitrite in Lung Transplant Patients to Minimize the Risk of Pulmonary Graft Dysfunction
This is a Phase 2 observational nonrandomized pilot investigation to evaluate the safety and efficacy of Sodium Nitrite administration for the reduction of Primary Graft Dysfunction (PGD) in patients undergoing lung transplant.
- Trial name
- NCT01715883
- Testing
- Sodium Nitrite
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gladwin, Mark, MD
Pulmonary Arterial Hypertension, Systemic Sclerosis
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease…
- Conditions
- Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease
- Trial name
- ATPAHSS (NCT01042158)
- Testing
- tadalafil and ambrisentan upfront combination therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Pulmonary Embolism, Thoracic Surgery
Chemoprophylaxis Plus Early Ambulation
Pulmonary embolism (PE) can be a devastating postoperative complication and the leading cause of mortality after thoracic surgery.
- Trial name
- NCT03862755
- Testing
- Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)
- Where
- China
- Volunteers
- 581 people
- Sponsor
- Shen Lei
Hypertension, Pulmonary, Pulmonary Disease, Chronic Obstructive
Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of a single oral dose of BAY63-2521 in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00640315
- Testing
- Riociguat (Adempas, BAY63-2521) 1.0 mg, Riociguat (Adempas, BAY63-2521) 2.5 mg
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Bayer
Heart Defects, Congenital
Safety and Performance of a Vascular Patch in Pediatric Patients Undergoing Bidirectional Cava-pulmonary Anastomosis
Xeltis developed biodegradable patch prosthesis, the Vascular Patch Model COR-VP-001, to be used as a vascular patch to augment the pulmonary trunk and pulmonary arteries.
- Trial name
- XEL-CR-06 (NCT02377700)
- Testing
- Xeltis Vascular Patch, Model COR-VP-001
- Where
- Russia
- Volunteers
- 5 people
- Sponsor
- Xeltis